Vista Pharmaceuticals Ltd (VISTAPH) is currently trading at 5.62 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vista Pharmaceuticals Limited is a formulation-focused pharmaceutical manufacturer based in Hyderabad that produces tablets, capsules and liquids primarily for gastrointestinal, pain management and anti-infective therapies; the company operates a cGMP, US‑FDA compliant facility and historically exported to the US, positioning Vista Pharmaceuticals Limited as a specialized generic/formulation player. Financially the company reported total income of INR 165.49 lakhs for Q2 FY2026 and INR 317.37 lakhs for the half year, with a sharp deterioration to a loss before tax of INR 362.21 lakhs in the quarter and INR 510.21 lakhs for the half, driven by high operating expenses and a large Expected Credit Loss provision at Vista Pharmaceuticals Limited. Balance sheet dynamics show material capital work‑in‑progress of INR 1,055.34 lakhs, tangible investments of INR 730.00 lakhs and almost exhausted cash at INR 13.26 lakhs at quarter end, while current borrowings increased to INR 624.15 lakhs — indicating Vista Pharmaceuticals Limited is investing to expand capacity but facing cash strain. Management recognized an Expected Credit Loss (ECL) provision of INR 205.43 lakhs against long‑pending receivables and completed a convertible warrant issuance (10,249,998 warrants) with 25% upfront proceeds of INR 307.50 lakhs, reflecting both a conservative credit approach and urgent capital raising activity by Vista Pharmaceuticals Limited.

Over the past 52 weeks, Vista Pharmaceuticals Ltd has traded between a low of ₹5.32 and a high of ₹10.43. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vista Pharmaceuticals Ltd has a market capitalization of approximately 35.95. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vista Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -3.06 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 35.95 Cr, Vista Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vista Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vista Pharmaceuticals Ltd is -3.06. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Vista Pharmaceuticals reported a net loss of Rs 98.59 lakh for the quarter ended June 30, 2026, narrowing from a loss of Rs 129.04 lakh in Q1 FY25.

The company informed BSE that its board meeting is scheduled on 14 August 2026 to consider unaudited financial results for the quarter ended 30 June 2026.